NKTR Nektar Therapeutics - Common Stock
$72,34
السعر · أغسطس 18, 2026
البيانات الأساسية اعتبارًا من أغسطس 14, 2026
نطاق 52 أسبوعًا
$25–$109
56% of range
تقييم المحللين
BUY
17 analysts
السعر المستهدف
$153
+112% upside
P/E (TTM)
-10.8
ROE
-500.1%
هامش صافي الربح
-297.1%
حول Nektar Therapeutics - Common Stock نظرة عامة على الشركة من ويكيبيديا
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
اقرأ المزيد
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Background
The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc.
In 2013, the company was assigned a patent which was developed by the company and other four co-inventors. The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide. As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion.
As of December 2024, at a stock price-per-share of roughly $1, the market cap is roughly $171 million. Nektar underwent periods of downsizing after unsuccessful partnerships were ended with Eli Lilly in 2023 and Bristol Myers Squibb in 2022, resulting in layoffs of most company employees.
Pipeline
Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016. The European Medicines Agency refused a marketing authorisation in 2017.
Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine, Phase I results were announced in November 2016. It is now in a phase 2 trial in combination with nivolumab for various advanced cancers.
In 2023 Nektar's partnership with Eli Lilly in development of "rezpeg" was ended. Eli Lilly claimed the drug lacked suitable efficacy, while Nektar responded that Eli Lilly had botched the analysis.
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
NKTR لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$72.34
القيمة السوقية
$2.13B
P/E (TTM)
-10.8
ربح السهم (آخر 12 شهرًا)
$-9.73
الإيرادات (آخر 12 شهرًا)
$55M
عائد التوزيعات
—
ROE
-500.1%
D/E الدين/حقوق الملكية
—
نطاق 52 أسبوعًا
$25 – $109
NKTR مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
Configure
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات وصافي الدخل
$55M
2016-12-31
→
2025-12-31
ربح السهم
$-9.73
2016-12-31
→
2025-12-31
التدفق النقدي الحر
$-209M
2016-12-31
→
2025-12-31
الهوامش
-297.1%
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
المقياس
اتجاه 5 سنوات
NKTR
متوسط الأقران
P/E (TTM)
-10.8
29.4
P/S (TTM) (السعر / المبيعات (آخر 12 شهرًا))
38.6
4.9
P/B (السعر / القيمة الدفترية)
23.7
6.5
Price / FCF (السعر / التدفق النقدي الحر)
-10.2
—
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
المقياس
اتجاه 5 سنوات
NKTR
متوسط الأقران
Operating Margin (هامش التشغيل)
-253.7%
—
Net Profit Margin (هامش صافي الربح)
-297.1%
-9.0%
ROA (العائد على الأصول)
-56.2%
-8.2%
ROE
-500.1%
-19.4%
ROIC
-155.8%
—
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
المقياس
اتجاه 5 سنوات
NKTR
متوسط الأقران
Current Ratio (النسبة الحالية)
5.0
3.6
Quick Ratio (النسبة السريعة)
0.3
—
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
المقياس
اتجاه 5 سنوات
NKTR
متوسط الأقران
Revenue YoY (الإيرادات مقارنة بالعام السابق)
-43.9%
—
Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات)
-15.7%
—
Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات)
-18.4%
—
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
المقياس
اتجاه 5 سنوات
NKTR
متوسط الأقران
NKTR توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
شراء
17 محللين
- شراء قوي 7 41,2%
- شراء 8 47,1%
- احتفاظ 2 11,8%
- بيع 0 0,0%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
9 محللين · 2026-08-16
الوسيط
$151.00
← أقل من جميع الأهداف
$72.34
منخفض
$80.00
مرتفع
$192.00
السعر المستهدف الوسيط
$151.00
+108,7%
السعر المستهدف المتوسط
$153.22
+111,8%
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
0.21%
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $-1.23 | $-2.02 | 0.79% |
| 31 مارس، 2026 | $-1.82 | $-1.63 | -0.19% |
| 31 ديسمبر، 2025 | $-1.78 | $-2.52 | 0.74% |
| 30 سبتمبر، 2025 | $-1.87 | $-2.74 | 0.87% |
| 30 يونيو، 2025 | $-2.95 | $-3.10 | 0.15% |
| 31 مارس، 2025 | $-3.60 | $-2.51 | -1.1% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| NKTR | $862M | -4.3 | -43.9% | -297.1% | -500.1% | — |
| ALMS | — | -3.4 | — | -1011.8% | -61.9% | — |
| TARS | $3.48B | -51.5 | 146.7% | -14.7% | -19.7% | — |
| SUPN | $2.86B | -73.1 | 8.6% | -5.4% | -3.6% | — |
| ATAI | $223M | -1.4 | -1.9% | -48464.0% | -83.1% | — |
| TRVI | $1.61B | -39.1 | — | — | -22.4% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| AMLX | $1.33B | -7.9 | -77.1% | — | -61.2% | — |
| PBH | $3.33B | 15.2 | -4.3% | 17.5% | 10.2% | 54.7% |
| RAPP | $1.45B | -10.6 | — | — | -29.8% | — |
| OCUL | $2.62B | -8.5 | -18.5% | -511.9% | -55.4% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Cost of Revenue | $0 | $31M | $34M | $22M | $25M | $19M | $21M | $24M | $31M | $30M | $34M | $29M | |
| R&D Expense | $117M | $121M | $114M | $218M | $400M | $409M | $435M | $400M | $268M | $204M | $183M | $148M | |
| SG&A Expense | $69M | $77M | $77M | $92M | $123M | $105M | $99M | $81M | $52M | $44M | $43M | $41M | |
| Operating Expenses | $195M | $204M | $354M | $468M | $548M | $578M | $555M | $505M | $367M | $278M | $260M | $217M | |
| Operating Income | $-140M | $-105M | $-264M | $-376M | $-446M | $-425M | $-440M | $688M | $-60M | $-113M | $-29M | $-16M | |
| Interest Expense | · | · | · | $0 | $0 | $7M | $21M | $22M | $22M | $22M | $18M | $18M | |
| Interest Income | $10M | $14M | $19M | $7M | $3M | · | · | · | · | · | · | · | |
| Other Non-op | $361.0K | $-390.0K | $-6M | $-116.0K | $-162.0K | $18M | $46M | $38M | $5M | $2M | $2M | $814.0K | |
| Pretax Income | $-164M | $-119M | $-276M | $-365M | $-523M | $-444M | $-440M | $683M | $-96M | $-153M | $-81M | $-54M | |
| Income Tax | $-138.0K | $-239.0K | $-200.0K | $3M | $557.0K | $493.0K | $613.0K | $1M | $616.0K | $876.0K | $506.0K | $-512.0K | |
| Net Income | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| EPS (Basic) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $4.02 | $-0.62 | $-1.10 | · | · | |
| EPS (Diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | · | · | |
| Shares (Basic) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 169,600,000 | 155,953,000 | 139,596,000 | · | · | |
| Shares (Diluted) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 180,119,000 | 155,953,000 | 139,596,000 | · | · | |
| EBITDA | $-140M | $-101M | $-257M | $-364M | $-433M | $-413M | $-429M | $697M | $-47M | $-113M | $-29M | · |
الميزانية العمومية 24
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $44M | $35M | $88M | $25M | $199M | $96M | $195M | $5M | $60M | $56M | $12M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $291M | $329M | $253M | $225M | |
| Receivables | · | $0 | $1M | $6M | $22M | $39M | $37M | $43M | $5M | $16M | $20M | $4M | |
| Inventory | $0 | $0 | $16M | $19M | $16M | $15M | $13M | $11M | $11M | $11M | $11M | $13M | |
| Other Current Assets | $21M | $6M | $10M | $16M | $23M | $22M | $15M | $21M | $8M | $10M | $10M | $9M | |
| Current Assets | $266M | $261M | $331M | $546M | $796M | $1.14B | $1.42B | $1.44B | $327M | $426M | $350M | $288M | |
| PP&E (Net) | $2M | $3M | $19M | $32M | $61M | $60M | $66M | $49M | $47M | $66M | $71M | $70M | |
| Accum. Depreciation | · | $16M | $87M | $125M | $148M | $138M | $128M | $121M | $115M | $111M | $103M | $94M | |
| Goodwill | · | · | $0 | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | |
| Other Non-current Assets | $14M | $5M | $5M | $2M | $3M | $1M | $344.0K | $4M | $994.0K | $817.0K | $754.0K | $7M | |
| Total Assets | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Accounts Payable | $11M | $12M | $10M | $13M | $10M | $22M | $19M | $6M | $5M | $3M | $2M | $3M | |
| Accrued Liabilities | $22M | $30M | $22M | $37M | · | · | · | · | · | · | · | $6M | |
| Current Liabilities | $54M | $61M | $51M | $68M | $85M | $116M | $354M | $82M | $56M | $72M | $61M | $64M | |
| Capital Leases | $65M | $83M | $99M | $113M | $126M | $136M | $143M | $0 | · | $2M | $1M | $4M | |
| Other Non-current Liabilities | $9M | $7M | $5M | $8M | $4M | $9M | $768.0K | $10M | $6M | $7M | $10M | $15M | |
| Total Liabilities | $191M | $243M | $267M | $344M | $438M | $461M | $572M | $433M | $421M | $481M | $492M | $405M | |
| Common Stock | $2.0K | $1.0K | $19.0K | $19.0K | $19.0K | $18.0K | $17.0K | $17.0K | $15.0K | $15.0K | $13.0K | $13.0K | |
| Retained Earnings | $-3.76B | $-3.60B | $-3.48B | $-3.20B | $-2.83B | $-2.31B | $-1.86B | $-1.42B | $-2.12B | $-2.02B | $-1.87B | $-1.79B | |
| Treasury Stock | · | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $17.0K | $61.0K | $80.0K | $-7M | $-4M | $-2M | $-1M | $-6M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $90M | $61M | $131M | $367M | $680M | $1.08B | $1.41B | $1.72B | $88M | $88M | $6M | $36M | |
| Liabilities + Equity | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Shares Outstanding | 20,378,832 | 12,385,001 | 12,757,984 | 188,560,000 | 185,468,000 | 180,091,000 | 176,505,000 | 173,530,000 | 159,524,000 | 153,212,000 | 135,289,000 | 131,216,000 |
التدفق النقدي 14
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $4M | $7M | $12M | $13M | $12M | $11M | $9M | $13M | $13M | $11M | $13M | |
| Stock-based Comp | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Deferred Tax | $64.0K | $-10.0K | $-140.0K | $3M | $-102.0K | $-36.0K | $-21.0K | $93.0K | $35.0K | $-115.0K | $-22.0K | $-31.0K | |
| Other Non-cash | · | $-61M | $77M | $49M | $98M | $119M | $101M | $28M | $4M | · | · | · | |
| Operating Cash Flow | $-209M | $-176M | $-193M | $-304M | $-413M | $-313M | $-329M | $718M | $-80M | $-117M | $-73M | $-142M | |
| CapEx | $171.0K | $1M | $865.0K | $6M | $15M | $7M | $26M | $14M | $10M | $6M | $11M | $10M | |
| Investing Cash Flow | $-1M | $143M | $140M | $366M | $203M | $496M | $207M | $-1.38B | $-29M | $-82M | · | · | |
| Stock Repurchased | $0 | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $0 | $-3M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $181M | $42M | $30.0K | $2M | $36M | $-80M | $23M | $852M | $54M | $204M | · | · | |
| Net Change in Cash | $-29M | $9M | $-53M | $63M | $-174M | $103M | $-99M | $190M | $-55M | $4M | $43M | $-27M | |
| Taxes Paid | $-195.0K | $76.0K | $3M | $272.0K | $325.0K | $539.0K | $555.0K | $618.0K | $556.0K | $757.0K | $860.0K | $964.0K | |
| Free Cash Flow | $-209M | $-177M | $-193M | $-310M | $-428M | $-321M | $-355M | $704M | $-90M | $-123M | $-84M | · | |
| Levered FCF | · | · | · | $-310M | $-428M | $-327M | $-376M | $682M | $-112M | $-146M | $-103M | · |
الربحية 7
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% | -19.4% | -68.2% | -12.7% | · | |
| Net Margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% | -35.2% | · | |
| Pretax Margin | -297.3% | -121.1% | -306.5% | -396.5% | -513.5% | -290.3% | -383.9% | 57.2% | -31.2% | -92.3% | -35.0% | · | |
| EBITDA Margin | -253.7% | -102.7% | -284.8% | -395.4% | -425.0% | -269.8% | -374.3% | 58.4% | -15.3% | -68.2% | -12.7% | · | |
| ROA | -56.2% | -33.9% | -49.8% | -40.3% | -39.5% | -25.3% | -21.3% | 51.2% | -17.9% | -28.8% | -17.2% | · | |
| ROE | -500.1% | -217.0% | -190.2% | -94.5% | -70.7% | -39.5% | -30.4% | 38.9% | -109.9% | -324.7% | -379.7% | · | |
| ROIC | -155.8% | -172.9% | -201.2% | -103.5% | -65.7% | -39.5% | -31.4% | 40.0% | -68.3% | -128.8% | -459.7% | · |
السيولة والملاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 | 9.8 | 4.0 | 17.5 | 5.8 | 5.9 | 5.7 | · | |
| Quick Ratio | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 | 2.1 | 0.4 | 2.9 | 5.4 | 5.6 | 5.4 | · | |
| Interest Coverage | · | · | · | · | · | -62.1 | -20.6 | 31.9 | -2.7 | -5.0 | -1.6 | · |
الكفاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.9 | 0.6 | 0.3 | 0.5 | · | |
| Inventory Turnover | · | 3.8 | 1.9 | 1.2 | 1.6 | 1.4 | 1.8 | 2.2 | 2.8 | 2.7 | 2.8 | · | |
| Receivables Turnover | · | 163.4 | 25.1 | 6.5 | 3.3 | 4.0 | 2.9 | 49.5 | 29.7 | 9.3 | 19.6 | · |
معدلات النمو 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -43.9% | 9.2% | -2.1% | -9.7% | -33.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -15.7% | -1.1% | -16.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -18.4% | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 10
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Net Income TTM | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| Market Cap | $862M | $2.59B | $1.61B | $6.39B | $37.59B | $45.92B | $57.16B | $85.56B | $142.90B | $28.20B | $34.19B | · | |
| P/E | -4.3 | -1.6 | -5.8 | -17.2 | -70.9 | -102.4 | -128.5 | 130.4 | -1444.8 | -167.3 | -414.3 | -516.7 | |
| P/S | 15.6 | 26.3 | 17.8 | 69.4 | 368.8 | 300.3 | 498.7 | 71.7 | 464.4 | 170.5 | 148.2 | · | |
| P/B | 9.6 | 42.7 | 12.3 | 17.4 | 55.3 | 42.6 | 40.7 | 49.8 | 1627.1 | 320.0 | 5318.8 | · | |
| P / Tangible Book | 9.6 | 42.7 | 12.3 | 22.0 | 62.3 | 45.9 | · | · | · | · | · | · | |
| P / Cash Flow | -4.1 | -14.7 | -8.3 | -21.0 | -91.1 | -146.6 | -173.9 | 119.1 | -1777.1 | -241.0 | -467.9 | · | |
| P / FCF | -4.1 | -14.6 | -8.3 | -20.6 | -87.9 | -143.3 | -161.0 | 121.5 | -1586.2 | -228.5 | -405.7 | · | |
| Earnings Yield | -23.0% | -62.2% | -17.3% | -5.8% | -1.4% | -0.98% | -0.78% | 0.77% | -0.07% | -0.60% | -0.24% | -0.19% |
قائمة الدخل 16
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $11M | $22M | $12M | $11M | $10M | $29M | $24M | $23M | $22M | $24M | $24M | $20M | $22M | $22M | $24M | |
| Cost of Revenue | · | · | $0 | $0 | $0 | $0 | $8M | $4M | $10M | $9M | $7M | $12M | $7M | $7M | $6M | $5M | |
| R&D Expense | $39M | $36M | $30M | $27M | $30M | $30M | $29M | $35M | $30M | $27M | $30M | $24M | $30M | $30M | $35M | $34M | |
| SG&A Expense | $13M | $13M | $11M | $16M | $17M | $24M | $17M | $19M | $21M | $20M | $17M | $21M | $18M | $21M | $22M | $23M | |
| Operating Expenses | $52M | $50M | $49M | $43M | $47M | $55M | $15M | $58M | $73M | $57M | $57M | $69M | $71M | $156M | $74M | $78M | |
| Operating Income | $-42M | $-39M | $-28M | $-32M | $-36M | $-45M | $14M | $-34M | $-50M | $-35M | $-34M | $-45M | $-51M | $-135M | $-52M | $-54M | |
| Interest Income | $9M | $4M | $3M | $3M | $2M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $4M | · | · | |
| Other Non-op | $-100.0K | $-336.0K | $-44.0K | $-121.0K | $260.0K | $266.0K | $-135.0K | $-120.0K | $-36.0K | $-99.0K | $-6M | $-335.0K | $736.0K | $-301.0K | $-4M | $2M | |
| Pretax Income | $-40M | $-43M | $-43M | $-35M | $-39M | $-46M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-57M | $-59M | |
| Income Tax | $2.0K | $64.0K | $31.0K | $-33.0K | $-188.0K | $52.0K | $-259.0K | $9.0K | $46.0K | $-35.0K | $-29.0K | $-61.0K | $-47.0K | $-63.0K | $3M | $-155.0K | |
| Net Income | $-41M | $-45M | $-36M | $-36M | $-42M | $-51M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-60M | $-59M | |
| EPS (Basic) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| EPS (Diluted) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| Shares (Basic) | 33,054,865 | 24,736,066 | -227,086,936 | 18,946,559 | 14,087,307 | 14,063,402 | -208,906,454 | 13,949,851 | 13,921,378 | 194,746,000 | -378,936,000 | 190,406,000 | 189,656,000 | 188,875,000 | -373,151,000 | 187,641,000 | |
| Shares (Diluted) | 33,054,865 | 24,736,066 | -227,086,936 | 18,946,559 | 14,087,307 | 14,063,402 | -208,906,454 | 13,949,851 | 13,921,378 | 194,746,000 | -378,936,000 | 190,406,000 | 189,656,000 | 188,875,000 | -373,151,000 | 187,641,000 | |
| EBITDA | $-42M | $-39M | · | $-32M | $-36M | $-45M | · | $-34M | $-50M | $-35M | · | $-45M | $-51M | $-135M | · | $-54M |
الميزانية العمومية 23
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39M | $150M | $15M | $41M | $43M | $39M | $44M | $30M | $28M | $49M | $35M | $65M | $51M | $77M | $88M | $106M | |
| Receivables | · | · | · | · | · | · | · | $0 | $1M | $4M | $1M | $2M | $1M | $3M | $6M | $12M | |
| Inventory | · | · | $0 | · | · | · | $0 | $0 | $14M | $16M | $16M | $15M | $21M | $20M | $19M | $19M | |
| Other Current Assets | $55M | $20M | $21M | $11M | $11M | $11M | $6M | $9M | $8M | $11M | $10M | $9M | $10M | $11M | $16M | $23M | |
| Current Assets | $739M | $589M | $266M | $281M | $187M | $230M | $261M | $286M | $295M | $320M | $331M | $399M | $441M | $491M | $546M | $599M | |
| PP&E (Net) | · | · | $2M | $3M | $3M | $3M | $3M | $4M | $15M | $17M | $19M | $20M | $23M | $27M | $32M | $37M | |
| Accum. Depreciation | · | · | · | · | · | · | · | $16M | $88M | · | $87M | $88M | $108M | $111M | $125M | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $77M | $77M | |
| Other Non-current Assets | $17M | $11M | $6M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $2M | $1M | $2M | $2M | |
| Total Assets | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Accounts Payable | $25M | $10M | $11M | $16M | $14M | $18M | $12M | $9M | $6M | $9M | $10M | $3M | $3M | $4M | $13M | $5M | |
| Accrued Liabilities | $23M | $25M | $22M | $29M | $35M | $31M | $30M | $32M | $30M | $24M | $22M | $30M | $29M | $37M | $37M | · | |
| Current Liabilities | $71M | $58M | $54M | $66M | $71M | $71M | $61M | $68M | $57M | $52M | $51M | $52M | $51M | $60M | $68M | $84M | |
| Capital Leases | $56M | $61M | $65M | $70M | $74M | $78M | $83M | $87M | $91M | $95M | $99M | $102M | $106M | $109M | $113M | $116M | |
| Other Non-current Liabilities | $8M | $8M | $9M | $5M | $6M | $7M | $7M | $7M | $8M | $4M | $5M | $5M | $5M | $6M | $8M | $3M | |
| Total Liabilities | $192M | $187M | $191M | $216M | $232M | $243M | $243M | $259M | $264M | $269M | $267M | $283M | $297M | $321M | $344M | $369M | |
| Common Stock | $3.0K | $3.0K | $2.0K | $2.0K | $1.0K | $19.0K | $1.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | |
| Retained Earnings | $-3.85B | $-3.81B | $-3.76B | $-3.72B | $-3.69B | $-3.65B | $-3.60B | $-3.60B | $-3.57B | $-3.51B | $-3.48B | $-3.44B | $-3.39B | $-3.34B | $-3.20B | $-3.14B | |
| Treasury Stock | · | · | · | $0 | $3M | $3M | $3M | $3M | $3M | $3M | · | · | · | · | · | · | |
| AOCI | $-2M | $-1M | $17.0K | $56.0K | $-14.0K | $39.0K | $61.0K | $355.0K | $-494.0K | $-403.0K | $80.0K | $-6M | $-6M | $-6M | $-7M | $-8M | |
| Stockholders' Equity | $903M | $576M | $90M | $85M | $-24M | $14M | $61M | $49M | $80M | $127M | $131M | $159M | $197M | $241M | $367M | $412M | |
| Liabilities + Equity | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Shares Outstanding | 20,378,832 | 20,378,832 | 20,378,832 | 19,652,513 | 12,457,252 | 186,103,000 | 12,385,001 | 184,458,000 | 184,061,000 | 183,624,000 | 191,384,000 | 190,771,000 | 190,119,000 | 189,235,000 | 188,560,000 | 187,954,000 |
التدفق النقدي 12
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $156.0K | $151.0K | $190.0K | $196.0K | $214.0K | $426.0K | $332.0K | $993.0K | $1M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $2.0K | $-31.0K | $57.0K | $-38.0K | $2M | $-15.0K | $-27.0K | $-2M | $3M | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Operating Cash Flow | $-76M | $-44M | $-65M | $-49M | $-46M | $-49M | $-46M | $-44M | $-38M | $-48M | $-47M | $-42M | $-52M | $-52M | $-58M | $-83M | |
| CapEx | $94.0K | $18.0K | $18.0K | $114.0K | $37.0K | $2.0K | $459.0K | $666.0K | $186.0K | $157.0K | $237.0K | $33.0K | $162.0K | $433.0K | $512.0K | $181.0K | |
| Investing Cash Flow | $-399M | $-351M | $372.0K | $-95M | $50M | $44M | $60M | $46M | $17M | $19M | $17M | $56M | $25M | $41M | $40M | $111M | |
| Stock Repurchased | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $-3M | · | · | · | · | · | · | |
| Financing Cash Flow | $365M | $530M | $39M | $142M | $211.0K | $7.0K | $83.0K | $13.0K | $19.0K | $42M | $12.0K | $0 | $18.0K | $0 | $103.0K | $0 | |
| Net Change in Cash | $-110M | $134M | $-26M | $-2M | $4M | $-5M | $14M | $2M | $-21M | $13M | $-30M | $14M | $-26M | $-11M | $-18M | $28M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | $272.0K | $-85.0K | |
| Free Cash Flow | · | $-44M | · | · | · | $-49M | · | · | · | $-48M | · | · | · | $-52M | · | · |
الربحية 7
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| Net Margin | -401.0% | -413.4% | · | -301.3% | -372.2% | -486.4% | · | -153.6% | -222.9% | -170.1% | · | -189.8% | -249.4% | -634.5% | · | -249.9% | |
| Pretax Margin | -397.8% | -396.7% | · | -297.0% | -352.5% | -443.3% | · | -153.6% | -222.7% | -170.2% | · | -190.1% | -249.6% | -634.8% | · | -250.6% | |
| EBITDA Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| ROA | -6.2% | -8.8% | · | -11.7% | -15.1% | -15.6% | · | -9.9% | -12.5% | -7.7% | · | -7.5% | -7.5% | -17.3% | · | -5.7% | |
| ROE | -9.2% | -15.2% | · | -53.0% | -150.0% | -72.5% | · | -35.6% | -37.9% | -20.0% | · | -16.0% | -15.6% | -32.3% | · | -9.7% | |
| ROIC | -4.7% | -6.8% | · | -37.2% | 148.9% | -324.5% | · | -70.3% | -62.5% | -27.9% | · | -28.1% | -25.7% | -55.9% | · | -13.1% |
السيولة والملاءة 2
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.4 | 10.2 | · | 4.2 | 2.6 | 3.2 | · | 4.2 | 5.1 | 6.1 | · | 7.7 | 8.7 | 8.2 | · | 7.1 | |
| Quick Ratio | 0.6 | 2.6 | · | 0.6 | 0.6 | 0.5 | · | 0.4 | 0.5 | 1.0 | · | 1.3 | 1.0 | 1.3 | · | 1.4 |
الكفاءة 3
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | · | · | · | · | · | · | · | 0.6 | 0.6 | 0.5 | · | 0.7 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | 21.9 | 18.6 | 6.5 | · | 3.5 | 3.6 | 1.3 | · | 1.2 |
التقييم (آخر 12 شهرًا) 10
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $44M | $44M | · | $58M | $69M | $80M | · | $93M | $90M | $88M | · | $90M | $87M | $92M | · | $95M | |
| Net Income TTM | $-163M | $-173M | · | $-165M | $-182M | $-177M | · | $-172M | $-186M | $-271M | · | $-293M | $-406M | $-446M | · | $-454M | |
| Market Cap | $1.42B | $1.47B | · | $1.12B | $322M | $1.90B | · | $3.60B | $3.42B | $2.56B | · | $1.72B | $1.65B | $1.99B | · | $9.02B | |
| P/E | -8.9 | -7.0 | · | -7.4 | -2.7 | -1.5 | · | -2.8 | -4.2 | -9.8 | · | -5.8 | -4.0 | -4.4 | · | -0.1 | |
| P/S | 32.4 | 33.1 | · | 19.4 | 4.6 | 23.8 | · | 38.5 | 38.1 | 29.1 | · | 19.1 | 18.9 | 21.7 | · | 94.9 | |
| P/B | 1.6 | 2.5 | · | 13.1 | -13.3 | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 21.9 | |
| P / Tangible Book | 1.6 | 2.5 | · | 13.1 | · | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 26.9 | |
| P / Cash Flow | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.5 | · | · | · | -38.3 | · | · | |
| P / FCF | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.3 | · | · | · | -38.0 | · | · | |
| Earnings Yield | -11.3% | -14.3% | · | -13.6% | -37.2% | -67.2% | · | -35.1% | -24.0% | -10.2% | · | -17.2% | -24.8% | -22.7% | · | -1649.3% |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $55M | $98M | $90M | $92M | $102M |
| هامش الربح التشغيلي % | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% |
| صافي الدخل | $-164M | $-119M | $-276M | $-368M | $-524M |
| EPS المخفف | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| النسبة الحالية | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 |
| النسبة السريعة | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 |
التدفق النقدي
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $-209M | $-177M | $-193M | $-310M | $-428M |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
📊
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 269 مقدمي إقرار · $2.1B إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 88 (+20 مقابل الربع السابق) | 41 (+9 مقابل الربع السابق) | 91 (+21 مقابل الربع السابق) | 48 (-8 مقابل الربع السابق) | +8.5M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| Two Seas Capital LP | $215868856 | 3092234 | 10,35% | الأسهم |
| FMR LLC | $192088149 | 2751585 | 9,21% | الأسهم |
| BVF INC/IL | $166920946 | 2391075 | 8,00% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $104495029 | 1496849 | 5,01% | الأسهم |
| TWO SIGMA INVESTMENTS, LP | $83911899 | 1202004 | 4,02% | الأسهم |
| Vestal Point Capital, LP | $69810000 | 1000000 | 3,35% | الأسهم |
| STATE STREET CORP | $63504691 | 909679 | 3,04% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57502497 | 823700 | 2,76% | عقد خيار الشراء |
| Prosight Management, LP | $56546100 | 810000 | 2,71% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $52759799 | 755586 | 2,53% | الأسهم |
| ARMISTICE CAPITAL, LLC | $50542440 | 724000 | 2,42% | الأسهم |
| GILDER GAGNON HOWE & CO LLC | $41946944 | 600873 | 2,01% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $33377557 | 478120 | 1,60% | الأسهم |
| BRAIDWELL LP | $33063203 | 473617 | 1,59% | الأسهم |
| Sofinnova Investments, Inc. | $32933775 | 471763 | 1,58% | الأسهم |
| Woodline Partners LP | $32871784 | 470875 | 1,58% | الأسهم |
| ORBIMED ADVISORS LLC | $32485804 | 465346 | 1,56% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $27540045 | 394500 | 1,32% | عقد خيار البيع |
| EMERALD ADVISERS, LLC | $27236930 | 390158 | 1,31% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $24331577 | 348540 | 1,17% | الأسهم |
| DAFNA Capital Management LLC | $22226108 | 318380 | 1,07% | الأسهم |
| Deep Track Capital, LP | $20943000 | 300000 | 1,00% | الأسهم |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19893826 | 284971 | 0,95% | الأسهم |
| 22NW, LP | $19624638 | 281115 | 0,94% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19475384 | 278977 | 0,93% | الأسهم |
| PRIMECAP MANAGEMENT CO/CA/ | $19047658 | 272850 | 0,91% | الأسهم |
| Nearwater Capital Markets, Ltd | $18255315 | 261500 | 0,88% | الأسهم |
| BARCLAYS PLC | $17968815 | 257396 | 0,86% | الأسهم |
| EMERALD MUTUAL FUND ADVISERS TRUST | $17842528 | 255587 | 0,86% | الأسهم |
| ADAR1 Capital Management, LLC | $17046485 | 244184 | 0,82% | الأسهم |
| Creek Drive Management Group LLC | $16963830 | 243000 | 0,81% | الأسهم |
| SEVEN GRAND MANAGERS, LLC | $16754400 | 240000 | 0,80% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $16724731 | 239575 | 0,80% | الأسهم |
| NORGES BANK | $15030093 | 215300 | 0,72% | الأسهم |
| Bronte Capital Management Pty Ltd. | $13852678 | 198434 | 0,66% | الأسهم |
| TWO SIGMA ADVISERS, LP | $13039744 | 308414 | 0,63% | الأسهم |
| CITADEL ADVISORS LLC | $12251655 | 175500 | 0,59% | عقد خيار البيع |
| GREAT POINT PARTNERS LLC | $12216750 | 175000 | 0,59% | الأسهم |
| Caption Management, LLC | $11944491 | 171100 | 0,57% | عقد خيار الشراء |
| MILLENNIUM MANAGEMENT LLC | $11867700 | 170000 | 0,57% | عقد خيار الشراء |
| CITADEL ADVISORS LLC | $11434878 | 163800 | 0,55% | عقد خيار الشراء |
| AMERIPRISE FINANCIAL INC | $11050085 | 158288 | 0,53% | الأسهم |
| Quinn Opportunity Partners LLC | $10686236 | 153076 | 0,51% | الأسهم |
| GOLDMAN SACHS GROUP INC | $10011801 | 143415 | 0,48% | الأسهم |
| Rhenman & Partners Asset Management AB | $9860662 | 141250 | 0,47% | الأسهم |
| Qube Research & Technologies Ltd | $9111671 | 130521 | 0,44% | الأسهم |
| LMR Partners LLP | $9075300 | 130000 | 0,44% | عقد خيار البيع |
| Soleus Capital Management, L.P. | $8960951 | 128362 | 0,43% | الأسهم |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $8570364 | 122767 | 0,41% | الأسهم |
| Stonepine Capital Management, LLC | $8422856 | 120654 | 0,40% | الأسهم |
| SummitTX Capital, L.P. | $7883923 | 112934 | 0,38% | الأسهم |
| APEIRON CAPITAL Ltd | $7429948 | 106431 | 0,36% | الأسهم |
| CITIGROUP INC | $7034824 | 100771 | 0,34% | الأسهم |
| ING GROEP NV | $6981000 | 100000 | 0,33% | الأسهم |
| LMR Partners LLP | $6981000 | 100000 | 0,33% | الأسهم |
| Susquehanna Portfolio Strategies, LLC | $6685704 | 95770 | 0,32% | الأسهم |
| Militia Capital Management LLC | $6282900 | 90000 | 0,30% | الأسهم |
| ACT CAPITAL MANAGEMENT, LLC | $6234033 | 89300 | 0,30% | الأسهم |
| Tetragon Partners GP Ltd | $6073191 | 86996 | 0,29% | الأسهم |
| READYSTATE ASSET MANAGEMENT LP | $5941529 | 85110 | 0,28% | الأسهم |
| Birchview Capital, LP | $5654610 | 81000 | 0,27% | الأسهم |
| BlackRock, Inc. | $5444412 | 77989 | 0,26% | الأسهم |
| GROUP ONE TRADING LLC | $4912600 | 70371 | 0,24% | الأسهم |
| ALGERT GLOBAL LLC | $4686345 | 67130 | 0,22% | الأسهم |
| Moody Aldrich Partners LLC | $4477264 | 64135 | 0,21% | الأسهم |
| WOLVERINE TRADING, LLC | $4330620 | 73500 | 0,21% | عقد خيار البيع |
| Swiss National Bank | $4300296 | 61600 | 0,21% | الأسهم |
| F/m Investments LLC | $4229439 | 60585 | 0,20% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $4227764 | 60561 | 0,20% | الأسهم |
| ExodusPoint Capital Management, LP | $4084374 | 58507 | 0,20% | الأسهم |
| Trexquant Investment LP | $3956831 | 56680 | 0,19% | الأسهم |
| K2 PRINCIPAL FUND, L.P. | $3522962 | 50465 | 0,17% | الأسهم |
| WOLVERINE TRADING, LLC | $3403101 | 57758 | 0,16% | الأسهم |
| RHUMBLINE ADVISERS | $3008381 | 43094 | 0,14% | الأسهم |
| MORGAN STANLEY | $2943050 | 42158 | 0,14% | الأسهم |
| Voleon Capital Management LP | $2850901 | 40838 | 0,14% | الأسهم |
| Anson Funds Management LP | $2829748 | 40535 | 0,14% | الأسهم |
| Atom Investors LP | $2828631 | 40519 | 0,14% | الأسهم |
| WOLVERINE TRADING, LLC | $2792808 | 47400 | 0,13% | عقد خيار الشراء |
| Burkehill Global Management, LP | $2792400 | 40000 | 0,13% | الأسهم |
| NOMURA HOLDINGS INC | $2792400 | 40000 | 0,13% | عقد خيار البيع |
| IRIDIAN ASSET MANAGEMENT LLC/CT | $2708768 | 38802 | 0,13% | الأسهم |
| NOMURA HOLDINGS INC | $2698645 | 38657 | 0,13% | الأسهم |
| Jefferies Financial Group Inc. | $2664299 | 38165 | 0,13% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $2590200 | 36000 | 0,12% | الأسهم |
| Connor, Clark & Lunn Investment Management Ltd. | $2575780 | 36897 | 0,12% | الأسهم |
| ALPS ADVISORS INC | $2386664 | 34188 | 0,11% | الأسهم |
| FRED ALGER MANAGEMENT, LLC | $2350712 | 33673 | 0,11% | الأسهم |
| TUDOR INVESTMENT CORP ET AL | $2345616 | 33600 | 0,11% | عقد خيار الشراء |
| Bank of New York Mellon Corp | $2306522 | 33040 | 0,11% | الأسهم |
| Ghisallo Capital Management LLC | $2233920 | 32000 | 0,11% | الأسهم |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $2063670 | 28682 | 0,10% | الأسهم |
| Blackstone Inc. | $2002011 | 28678 | 0,10% | الأسهم |
| KVP Capital Advisors, LP | $1877889 | 26900 | 0,09% | الأسهم |
| Ishara Investments LP | $1860437 | 26650 | 0,09% | الأسهم |
| Erste Asset Management GmbH | $1830920 | 28000 | 0,09% | الأسهم |
| Caption Management, LLC | $1822041 | 26100 | 0,09% | عقد خيار البيع |
| WINTON GROUP Ltd | $1808079 | 25900 | 0,09% | الأسهم |
| K2 PRINCIPAL FUND, L.P. | $1745250 | 25000 | 0,08% | عقد خيار الشراء |
| Empowered Funds, LLC | $1636416 | 23441 | 0,08% | الأسهم |
المطلعون على الشركة 40 من المطلعين · مسؤولون 20 · مديرون 18
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Howard W Robin | President & CEO | 24 يوليو، 2026 A | 55045 | 0 | 20 | $-2224055 |
| Jillian B. Thomsen | Chief Financial Officer | 16 فبراير، 2023 S | 313497 | 0 | 0 | $0 |
| Gil M Labrucherie | SVP, COO & CFO | 16 مايو، 2022 S | 312905 | 0 | 0 | $0 |
| Timothy Harkness | SVP & Chief Financial Officer | 23 أغسطس، 2007 A | — | 0 | 0 | $0 |
| Louis Drapeau | Sr. VP Finance, CFO | 14 مايو، 2007 A | 6000 | 0 | 0 | $0 |
| Milton J Harris | President of Nektar AL | 4 مارس، 2004 S | 743904 | 0 | 0 | $0 |
| John Nicholson | SVP & Chief Operating Officer | 16 أغسطس، 2019 S | 162759 | 0 | 0 | $0 |
| Bharat M Chowrira | Chief Operating Officer | 1 فبراير، 2010 A | — | 0 | 0 | $0 |
| Jonathan Zalevsky | Chief R&D Officer | 24 يوليو، 2026 A | 9756 | 0 | 12 | $-1052364 |
| Mark Andrew Wilson | Chief Legal Officer | 21 نوفمبر، 2025 A | 21585 | 0 | 2 | $-52171 |
| John Northcott | SVP & Chief Commercial Officer | 16 مايو، 2022 S | 223210 | 0 | 0 | $0 |
| Stephen K Doberstein | SVP & Chief Scientific Officer | 5 سبتمبر، 2019 P | 107668 | 0 | 0 | $0 |
| Maninder Hora | SVP Pharma Dev & Mfg Ops | 16 مايو، 2019 S | 94694 | 0 | 0 | $0 |
| Ivan P. Gergel | SVP & Chief Medical Officer | 15 نوفمبر، 2017 A | 56553 | 0 | 0 | $0 |
| Robert Medve | SVP & Chief Medical Officer | 5 فبراير، 2014 A | — | 0 | 0 | $0 |
| Rinko Ghosh | Chief Business Officer | 6 فبراير، 2013 A | 9753 | 0 | 0 | $0 |
| Randall W Moreadith | SVP Drug Development | 23 فبراير، 2009 A | — | 0 | 0 | $0 |
| John Stuart Patton | Chief Scientific Officer | 14 نوفمبر، 2008 M | 313880 | 0 | 0 | $0 |
| Nevan C Elam | SVP & Head of Pulmonary Bus | 25 فبراير، 2008 A | 1400 | 0 | 0 | $0 |
| David Johnston | SVP, Research & Development | 14 مايو، 2007 D | 6600 | 0 | 0 | $0 |
| Diana Brainard | مدير | 30 سبتمبر، 2025 A | 28560 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | مدير | 30 سبتمبر، 2025 A | 34153 | 0 | 0 | $0 |
| Robert Chess | مدير | 30 سبتمبر، 2025 A | 255273 | 0 | 0 | $0 |
| Scott R Greer | مدير | 30 سبتمبر، 2025 A | 303574 | 0 | 0 | $0 |
| Roy A Whitfield | مدير | 30 سبتمبر، 2025 A | 216250 | 0 | 0 | $0 |
| Myriam Curet | مدير | 19 سبتمبر، 2023 A | 27418 | 0 | 0 | $0 |
| Karin Eastham | مدير | 16 سبتمبر، 2022 A | 23233 | 0 | 0 | $0 |
| Lutz Lingnau | مدير | 22 سبتمبر، 2020 A | 35800 | 0 | 0 | $0 |
| Christopher A Kuebler | مدير | 27 سبتمبر، 2018 A | 45250 | 0 | 0 | $0 |
| Dennis L Winger | مدير | 21 أغسطس، 2018 M | 42750 | 0 | 0 | $0 |
| Joseph J Krivulka | مدير | 19 سبتمبر، 2017 A | 82000 | 0 | 0 | $0 |
| Susan Wang | مدير | 20 نوفمبر، 2015 M | 20000 | 0 | 0 | $0 |
| BROWN MICHAEL A/CA | مدير | 15 سبتمبر، 2009 A | 10000 | 0 | 0 | $0 |
| Hoyoung Huh | مدير | 2 ديسمبر، 2008 A | — | 0 | 0 | $0 |
| Irwin Lerner | مدير | 2 ديسمبر، 2008 A | 10000 | 0 | 0 | $0 |
| James B Glavin | مدير | 4 سبتمبر، 2003 A | — | 0 | 0 | $0 |
| Masuoka K. Lorianne | — | 8 فبراير، 2011 A | — | 0 | 0 | $0 |
| Ajit Gill | President & CEO | 23 مارس، 2006 S | 87991 | 0 | 0 | $0 |
| Ajay Bansal | — | 10 مارس، 2006 S | 5166 | 0 | 0 | $0 |
| Melvin Perelman | — | 2 سبتمبر، 2004 A | — | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 1 حيازة
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Nektar Therapeutics ( | 22 أغسطس، 2005 | — | إيداع أولي | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 28 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3,14% | 50876 NS | 31 مايو، 2026 | N-PORT |
| SPIT · RBB Fund, Inc. | 3,11% | 10455 NS | 30 إبريل، 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,55% | 2353 NS | 30 إبريل، 2026 | N-PORT |
| BBC · ETFis Series Trust I | 1,15% | 5045 NS | 30 إبريل، 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,58% | 1726 SH | 8 أغسطس، 2026 | يومي |
| IHE · iShares Trust | 0,55% | 120730 SH | 8 أغسطس، 2026 | يومي |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 59612 SH | 8 أغسطس، 2026 | يومي |
| IWO · iShares Trust | 0,14% | 278376 SH | 8 أغسطس، 2026 | يومي |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,13% | 33135 SH | 8 أغسطس، 2026 | يومي |
| TMFX · RBB Fund, Inc. | 0,09% | 455 NS | 31 مايو، 2026 | N-PORT |
| IWM · iShares Trust | 0,08% | 877973 SH | 8 أغسطس، 2026 | يومي |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 198365 SH | 8 أغسطس، 2026 | يومي |
| ISCV · iShares Trust | 0,07% | 6414 SH | 8 أغسطس، 2026 | يومي |
| SCHA · SCHWAB STRATEGIC TRUST | 0,04% | 151830 NS | 31 مايو، 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 11131 NS | 30 إبريل، 2026 | N-PORT |
| ISCB · iShares Trust | 0,03% | 1294 SH | 8 أغسطس، 2026 | يومي |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 387471 SH | 8 أغسطس، 2026 | يومي |
| VHT · VANGUARD WORLD FUND | 0,03% | 92340 SH | 8 أغسطس، 2026 | يومي |
| WSML · iShares Trust | 0,02% | 1887 SH | 8 أغسطس، 2026 | يومي |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 3096 SH | 8 أغسطس، 2026 | يومي |
| IWN · iShares Trust | 0,02% | 32466 SH | 8 أغسطس، 2026 | يومي |
| ONEQ · Fidelity Commonwealth Trust | 0,00% | 6903 NS | 31 مايو، 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 48124 SH | 8 أغسطس، 2026 | يومي |
| IWV · iShares Trust | 0,00% | 9139 SH | 8 أغسطس، 2026 | يومي |
| TILT · FlexShares Trust | 0,00% | 770 NS | 30 إبريل، 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 18540 NS | 31 مايو، 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1075430 SH | 8 أغسطس، 2026 | يومي |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2837 SH | 8 أغسطس، 2026 | يومي |